ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated. If you have any questions, please contact Marianne Reed at mreed@ku.edu .

Show simple item record

dc.contributor.authorXie, Yumei
dc.contributor.authorBagby, Taryn Rochelle
dc.contributor.authorCohen, Mark S.
dc.contributor.authorForrest, M. Laird
dc.date.accessioned2017-06-12T19:34:00Z
dc.date.available2017-06-12T19:34:00Z
dc.date.issued2009-08
dc.identifier.citationXie, Y., Bagby, T. R., Cohen, M., & Forrest, M. L. (2009). Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies. Expert Opinion on Drug Delivery, 6(8), 785–792. http://doi.org/10.1517/17425240903085128en_US
dc.identifier.urihttp://hdl.handle.net/1808/24474
dc.descriptionThis is an Accepted Manuscript of an article published by Taylor & Francis in Expert Opinion on Drug Delivery on 2009-08, available online: http://www.tandfonline.com/10.1517/17425240903085128.en_US
dc.description.abstractCancer is the second leading cause of death in the US. Currently, protocols for cancer treatment include surgery to remove diseased and suspect tissues, focused radiation, systemic chemotherapy, immunotherapy and their combinations. With conventional chemotherapy, it is almost impossible to deliver anticancer drugs specifically to the tumor cells without damaging healthy organs or tissues. Over the past several decades, efforts have been made to improve drug delivery technologies that target anticancer drugs specifically to tumor cells. It has been known for over four decades that the lymphatics are the first site of metastasis for most solid cancers; however, few efforts have been made to localize chemotherapies to lymphatic tissues. Trials of several systemic targeted drug delivery systems based on nanoparticles containing chemotherapeutic agents (e.g., liposomal doxorubicin) have shown similar antitumor activity but better patient tolerance compared with conventional formulations. Animal studies have demonstrated that nanoparticles made of natural or synthetic polymers and liposomal carriers have higher accumulation in the lymph nodes and surrounding lymphatics compared to conventional intravenous therapies. This combination has the potential to both reduce nonspecific organ toxicities and increase the chemotherapeutic dose to the most likely sites of locoregional cancer metastasis.en_US
dc.publisherTaylor & Francisen_US
dc.subjectCancer diagnosisen_US
dc.subjectChemotherapiesen_US
dc.subjectLiposomesen_US
dc.subjectNanoparticlesen_US
dc.subjectLymphaticsen_US
dc.titleDrug delivery to the lymphatic system: importance in future cancer diagnosis and therapiesen_US
dc.typeArticleen_US
kusw.kuauthorXie, Yumei
kusw.kuauthorBagby, Taryn R.
kusw.kuauthorForrest, M. Laird
kusw.kudepartmentPharmaceutical Chemistryen_US
dc.identifier.doi10.1517/17425240903085128en_US
kusw.oaversionScholarly/refereed, author accepted manuscripten_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.identifier.pmidPMC3102644en_US
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record